Lung Cancer Research in South West England
Lung cancer research initiatives, studies, and recruitment in the South West and West of England. Details on ongoing studies, sites, recruitment numbers, and managed recovery efforts by NIHR for multi-site studies.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Lung Cancer research in the South West and West of England Claire Matthews, Ashley Cox and Joanne Taylor WE CRN and SW Pen CRN
Lung Cancer studies on the NIHR Portfolio Period 20/21-current: 4 managed recovery studies 2 studies led by CRN WE 1 study led by CRN SW Pen 12 Studies currently open to recruitment
Short Name Sites Opening date Closure date Target (Eng) Recruits Pleural effusion biomarker study (WE) Respiratory NBT 11/03/2008 31/01/2026 2533 1,543 ASSESS-meso (WE) Respiratory Plymouth, NBT, RUH 07/06/2017 05/04/2027 700 177 IMreal (SW Pen) GWH, Torbay, RCH, RUH 11/03/2019 15/06/2023 71 186 ETOP 13-18 BEAT-meso RCH, Plymouth 30/08/2019 15/04/2022 90 97 Derriford 15/05/2018 31/12/2021 30 8 Chemo +/- MK-3475 as Perioperative Therapy for Resectable NSCLC UHBW, RDE 31/03/2015 30/09/2022 412 328 National Lung Matrix: Multi-Drug Phase II trial in NSC Lung Cancer SARON UHBW 11/08/2016 31/03/2021 295 99 Mirati 516-005 RCH 13/05/2021 15/07/2022 8 5 RCH, Glos 13/04/2018 16/12/2021 52 35 Adjuvant canakinumab vs placebo in stages II-IIIB resected NSCLC SYMPLIFY Torbay, RCH 05/07/2021 30/09/2021 5,200 1,814 UHBW, RDE 06/09/2011 31/12/2021 19,400 14,855 CR UK Stratified Medicine Pilot study ICI Genetics N. Devon, RCH, Somerset, 12/04/2019 31/03/2024 1,000 299
Recruitment to Lung Cancer studies * ** *175 from SYMPLIFY - Observational study to assess a multi-cancer early detection test in individuals referred with signs and symptoms of cancer. **180 from SYMPLIFY 59 from Pleural Effusion Biomarker study 50 from CR UK Stratified Medicine Pilot study
Managed Recovery (MR) - Requested by DHSC, NIHR is working with funders, NHS R&D, research partners across the UK and patients and the public on a process to manage the recovery of multi-site studies. Stage 1: Funders identified the most urgent studies Stage 2: National Speciality Leads reviewed their portfolio to assess other studies that fell into scope. - Research delivery teams worked with LCRNs and R&D leadership to discuss and assess site, regional and national delivery capacity and capability. - https://www.nihr.ac.uk/researchers/managing-research-recovery.htm
This process has: Generated a list of studies that the funders and sponsors consider to be the most urgent to resume once capacity becomes available Studies are: Interventional, multi-site, urgent and require the support of NIHR CRN and its Devolved Administration equivalents Initial focus: Studies which can fully recruit and/or close in the next year Studies which are already open and recruiting successfully should not be paused in anticipation of, or as a result of, this process.
CRN High Level Objectives (HLOs) Efficient Study Delivery metrics: Proportion of new commercial studies closed in the year (Mar 21-Apr 22) recruiting to time and target Proportion of commercial studies in the MR process recruiting to time and target Proportion of non-commercial studies in the MR process recruiting to time and target These are being measured at study level.
Lung Cancer Studies Selected for MR CR UK Stratified Medicine Pilot study closing 31/12/21 Amber 14,855/19,400 (76.5%) recruited. Closure date being brought forward to 31/08/21 UHBW: Adam Dangoor 145/75 recruited National Lung Matrix: Multi-Drug Phase II trial in NSC Lung Cancer closing 30/09/22 Amber 328/412 recruited (Not included in HLO Metrics) UHBW: Adam Dangoor 14/5 recruited closing Adjuvant canakinumab vs placebo in stages II-IIIB resected NSCLC (Canopy-A) 16/12/21 Amber 37/52 recruited. At-home treatment was discussed by sponsor but rejected. BHOC: Gareth Ayres, recruitment 6/8 Cheltenham: David Farrugia, recruitment 1/6 Chemo +/- MK-3475 as Perioperative Therapy for Resectable NSCLC closing 31/12/21 Red 8/30 recruited. Sponsor aware that neoadjuvant trials hard to recruit to in the UK
Research Delivery Managers West of England: claire.matthews@nihr.ac.uk South West Peninsula: joannetaylor1@nhs.net Research Portfolio Facilitator iqra.hussain@nihr.ac.uk Lung Cancer Sub-specialty Lead (West of England) ashley.cox@nhs.net
